The global glioma diagnosis and treatment market is projected to have a startling growth at a
whopping 10.1% CAGR over the assessment period (2017-2023). Glioma is a kind of tumor that
forms in the brain. It is also called primary brain tumor. It is of various types and are entitled
resting on the cell type’s origin including glioblastoma, ependymomas, astrocytoma and
oligodendrogliomas. Glioma is the most common brain tumor and about 33% brain tumors are
Request Sample Copy:
There are many factors that is driving the growth of the glioma diagnosis and treatment
market. Some of these factors as per the Market Research Future (MRFR) report include rising
prevalence of brain cancer, innovations in brain cancer drugs, introduction of new and effective
therapies, rising geriatric population, current unmet needs, increasing awareness among
people, access to healthcare facilities, changing financial demands, existence of metastatic
tumors and growing medical tourism.
The market report offers an all-inclusive segmental analysis of the glioma diagnosis and
treatment market on the basis of type, diagnosis, treatment, grade, location and end-user.
Based on type, it is segmented into primary and secondary tumors. Primary tumors are further
segmented into mixed gliomas, optic nerve glioma, brainstem glioma, oligodendrogliomas,
astrocytoma and ependymomas. The ependymomas is again segmented into anaplastic
ependymomas (grade iii), ependymomas (grade ii), myxopapillary ependymomas (grade i) and
subependymomas (grade i). The astrocytomas is segmented into benign astrocytomas,
glioblastoma multiforme and anaplastic astrocytomas. The optic nerve glioma is segmented
into benign optic nerve glioma and malignant optic nerve glioma.
Based on diagnosis, the glioma diagnosis and treatment market is segmented into
Electroencephalography (EEG), molecular testing, biopsy, Positron Emission Tomograph